Iovance Biotherapeutics (NASDAQ:IOVA) Earns Buy Rating from HC Wainwright
HC Wainwright reiterated their buy rating on shares of Iovance Biotherapeutics (NASDAQ:IOVA – Free Report) in a research report released on Friday morning,Benzinga reports. The firm currently has a $32.00 price objective on the biotechnology company’s stock. HC Wainwright also issued estimates for Iovance Biotherapeutics’ Q1 2025 earnings at ($0.23) EPS and Q4 2025 earnings […]
HC Wainwright reiterated their buy rating on shares of Iovance Biotherapeutics (NASDAQ:IOVA – Free Report) in a research report released on Friday morning,Benzinga reports. The firm currently has a $32.00 price objective on the biotechnology company’s stock. HC Wainwright also issued estimates for Iovance Biotherapeutics’ Q1 2025 earnings at ($0.23) EPS and Q4 2025 earnings […]
